Cardlytics (CDLX) reported an adjusted loss of $1.03 per share on revenue of $32.88 million for the third quarter. Earnings Whispers' normalized figures show earnings up 24.3% year over year and revenue down 36.8%. No consensus figures were available for comparison. Management's own scorecard was blunt, though. CEO Amit Gupta opened by conceding that results "came in below expectations." Adjusted contribution of $19.4 million fell short of the company's $20–23 million guide, and revenue missed the $34–39 million range. The central tension is a business that keeps getting leaner and more efficient per dollar while getting smaller, and the balance sheet is losing room to wait for the top line to turn.

The figures need to be read carefully. Earnings Whispers' normalized comparison shows earnings improving, but the company's non-GAAP adjusted net loss widened to $1.03 per share from $0.58 a year ago. GAAP loss per share from continuing operations narrowed sharply, to $1.26 from $13.14. That improvement mostly reflects a $58.8 million impairment in the prior-year quarter rather than better operations. Likewise, the company reports revenue down 30% against a prior-year figure that includes divested-business effects, while Earnings Whispers' normalized decline is 36.8%. Either way, contraction is the story. Billings fell 32% to $57.2 million, and adjusted EBITDA slid to just $0.4 million from $3.3 million a year ago and $1.7 million in Q2. Free cash flow improved to -$1.6 million from -$10.7 million in Q2. However, that figure adds back $6.4 million of legal indemnification payments. On a GAAP basis, operating cash flow was -$5.9 million, so the quality of the cash-flow improvement deserves scrutiny.

Cost discipline was real. R&D expense halved year over year to $3.7 million, G&A fell 31%, and stock-based compensation dropped to $1.6 million from $6.4 million. Adjusted contribution margin rose to 59.0% of revenue, up from 57.7% in Q2 and 54.4% a year ago. That is the strongest evidence for the CFO's claim of "a higher contribution margin." The problem is volume:

• **Billings reversal:** Billings fell back to roughly Q1 levels from $65.5 million in Q2, breaking the commitment management made earlier this year to grow sequentially throughout 2026.
• **UK weakness:** UK billings fell 4% year over year after growth of 35%, 21% and 10% in the prior three quarters. Management blamed an extended technical disruption at a bank partner.
• **Advertiser budgets:** Grocery advertisers pulled back on macro pressure, and some budgets migrated to other formats.
• **User base:** Monthly qualified users ticked up sequentially to 187 million but remain down 19% year over year.

The call did preserve a credible supply-expansion narrative. Cardlytics signed four partners for its card-linked rewards program (CRP):

• Yahoo, with offers coming to Yahoo Mail;
• Vodafone's 3 UK, its first open-banking and first non-bank CRP partner at scale in the UK;
• the airline-miles program Rove;
• the loyalty platform Coopert, signed after the quarter.

That compares with three small pilots in Q1 and only "strong interest" in Q2. More than half of CRP-linked cards now come from outside the bank network, which matters given the company's heavy dependence on Chase and Wells Fargo. Demand-side green shoots included:

• new-business billings up 25% sequentially;
• the Q2 advertiser cohort growing billings 58%, with 70% renewing;
• boosted rewards for lapsed redeemers lifting billings 13% in test groups.

The Q4 guide calls for billings of $63–69 million and revenue of $35–39 million, both nudged above the Q3 ranges. Yet Earnings Whispers flags the outlook as below estimates. The adjusted EBITDA guide of -$1 million to +$2 million now extends into negative territory.

Liquidity is where bears have the most legitimate ammunition. Cash ended at $29.9 million against $169.7 million of convertible notes and $25 million drawn on the credit line. Available credit roughly halved to about $10.4 million from about $20 million. Management said it is "actively evaluating any and all options" to improve the balance sheet. That is a notably more defensive framing than Q2's talk of seeing results from the reset, and the stockholders' deficit widened to $23 million.

The market had already turned skeptical before the report. Shares closed at $2.19 on the eve of earnings, down 45.1% from the $3.99 open after the August report. They sat 6.1% below the 200-day moving average and 55.4% below the August 19 high of $4.91. They had, however, rebounded 39.5% from the October 28 low of $1.57. Earnings Whispers investor sentiment weakened meaningfully, from -0.18 to -0.35. The trend signals lean negative, with price and AVWAP trends both negative.

The bottom line is that Cardlytics delivered a quarter of improving unit economics and genuinely broader partner supply, wrapped around a guidance miss, a broken sequential-growth pledge and shrinking financial flexibility. The new CRP partners and the Q4 billings guide give the recovery case something tangible. Investors, however, will need to see Q4 actually deliver sequential growth, and get clarity on the balance-sheet options, before the efficiency gains outweigh the liquidity risk.